BRISBANE, Calif., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the Leerink Rare Disease Roundtable on Wednesday, October 1, 2014, at 9:15 a.m. ET. Donald J. Santel, chief executive officer, will provide a company overview. To access the live webcast and subsequent archived recording, please visit Hyperion’s website at http://investors.hyperiontx.com/events.cfm.
About Hyperion Therapeutics
Hyperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases. The company’s first commercial product, RAVICTI® (glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. The company also owns worldwide rights to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder, which it markets in the U.S. The compound is also marketed internationally through business partners. In addition, the company is developing glycerol phenylbutyrate for the potential treatment of hepatic encephalopathy. For more information, please visit www.hyperiontx.com.
CONTACT: Myesha Edwards Corporate Communications and Investor Relations (650) 745-7829
Help employers find you! Check out all the jobs and post your resume.
